Singleton inhibitors of sumoylation enzymes and methods for their use
US9238654B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | May 9, 2013 |
| Grant date | Jan 19, 2016 |
| Priority date | — |
| Expiry date | Mar 18, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D493/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
According to the embodiments described herein, a SUMOylation inhibitor compound comprising a singleton scaffold is provided. In some embodiments, a method for inhibiting a SUMOylation enzyme in a cell is provided. Such a method may include administering a SUMOylation inhibitor compound to the cell. In some aspects, the SUMOylation enzyme is SUMO E1 or SUMO E2. In some aspects, the method may be used to inhibit a cancer cell in vitro (e.g., grown in culture) or in vivo (e.g., as part of a tumor in a subject). In other embodiments, a method for treating a cancer, degenerative diseases and viral infection is provided. Such a method may include administering an effective amount of a pharmaceutical composition to a subject having the cancer. The pharmaceutical composition may include a singleton SUMOylation inhibitor compound. In some embodiments, the method for treating a cancer may further comprise administering one or more DNA-damaging therapy in combination with administration of the pharmaceutical composition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.